Submit RFI/RFP
Request Consultation
The FDA maintains a rigorous post-market surveillance system to protect public health through advanced Pharmacovigilance. Central to this is the FAERS (FDA Adverse Event Reporting System), a critical database used for Medical Monitoring and identifying potential Safety Signals associated with drugs and biologics. Also, FDA emphasized the importance of its quarterly reporting process, which is a cornerstone of global Signal Management strategies.
What Does Inclusion on the FAERS List Mean?
It is crucial to understand that if a drug appears on the FDA’s quarterly list, it does not mean a confirmed causal risk has been established. Instead, it indicates:
- Potential Safety Signals are currently being evaluated by regulatory experts.
- A need for further Aggregate Reporting and data analysis to confirm the risk.
- Safety Advice: Patients and prescribers should not stop using the medication without consulting a healthcare professional.
How the FDA Identifies Potential Safety Signals
The process is mandated by the 2007 FDA Amendments Act, requiring the agency to screen the safety database and implement effective Signal Management.
The Evaluation Workflow:
- Medical Monitoring: Safety staff in CDER and CBER routinely mine FAERS for patterns and adverse event trends.
- Pharmacovigilance Analysis: Once a “serious risk” is identified, it is logged into internal tracking systems for further scrutiny.
- Quarterly Publication: These findings are released to the public to ensure transparency for clinicians and stakeholders.
Regulatory Actions and Transparency
The goal of this Pharmacovigilance service is to increase transparency. If a safety signal is validated, the FDA may take measures such as:
- Labeling Changes: Updating safety warnings based on new data.
- REMS: Risk Evaluation and Mitigation Strategies.
- Drug Safety Communications: Issuing official alerts to the public.
Staying Updated
A fresh report is posted every quarter with newly identified signals. Once all issues in a report are resolved through finalized Aggregate Reporting and regulatory decision-making, the report is moved to the archived section.
To explore the latest data, visit the official FDA Signals of Serious Risks (FAERS) page.
Submit RFI/RFP